Four out of five Americans living with obstructive sleep apnea have no idea they have it. Their throats are collapsing dozens of times each night, oxygen is dropping, and their bodies are quietly accumulating damage to the heart, blood vessels, and metabolic system – all while they sleep. The striking part isn’t that so many people are undiagnosed. It’s that the ones who are diagnosed and can’t tolerate the standard treatment may now have a better option than anyone expected.
A small implanted device, roughly the size of a cardiac pacemaker, is showing results that researchers didn’t fully anticipate. People who received it were significantly less likely to develop diabetes two years after implantation compared to those who went untreated. The scale of that difference is what’s getting attention in sleep medicine right now.
The device works by targeting a nerve most people have never heard of: the hypoglossal nerve, which controls the movement of the tongue. In obstructive sleep apnea (OSA), the soft tissue at the back of the throat – including the tongue – relaxes during sleep and collapses inward, blocking airflow. A 2025 analysis published in Respiratory Medicine estimated that approximately 83.7 million U.S. adults are living with OSA, a condition in which soft tissue at the back of the throat collapses and blocks the airway during sleep, causing shallow or irregular breathing that lowers oxygen levels and raises the risk of diabetes and cardiovascular disease. Most of them are reaching for a CPAP machine – or struggling to.
How the “Tongue Pacemaker” Actually Works
Hypoglossal nerve stimulation (HGNS) involves the implantation of a small, FDA-approved device that delivers mild electrical impulses to the hypoglossal nerve during sleep, activating the muscles of the tongue and other airway muscles to keep the airway open and prevent episodes of apnea. The device consists of three components: a pulse generator, a breathing sensor, and a stimulation lead. The pulse generator sits under the skin in the chest, while the stimulation lead wraps around the hypoglossal nerve in the neck. During sleep, when the breathing sensor detects inhalation, the pulse generator delivers a mild electrical impulse to the nerve – activating the tongue and airway muscles to prevent collapse. When you exhale, the impulse stops and the muscles relax.
Research indicates that HGNS, a surgical procedure that offers an alternative to PAP machines for patients with obstructive sleep apnea, may lower the risk of diabetes and high blood pressure. The device received FDA approval in 2014 for patients with moderate-to-severe sleep apnea who failed CPAP therapy. Since then, eligibility criteria have expanded: as of 2023, the FDA specifies that a candidate’s apnea-hypopnea index (AHI) – a measure of how many breathing disruptions occur per hour of sleep – should be between 15 and 100, with a BMI under 40.
It isn’t a fit for everyone. The device works best when airway collapse follows a specific pattern, and a sleep specialist typically performs an endoscopic assessment before recommending it. But for the right patient – particularly someone who finds a CPAP mask unbearable – research published in the journal Sleep confirms HGNS is an effective treatment for OSA in patients who are intolerant to CPAP therapy.
The New Study: What 7,000 Patients Showed
The research driving current discussion was published in July 2026 in JAMA Otolaryngology – Head & Neck Surgery. Researchers analyzed adults who underwent HGNS between 2015 and 2024, matching them with controls who had OSA, were nonadherent to positive airway pressure therapy, but did not receive the implant. The study included 3,786 people who received HGNS and 3,395 controls. The median age of the implant group was 53 years, and 67.7% were male.
Among people without cardiovascular disease at baseline, HGNS was not associated with a diabetes diagnosis during the first two years. After two years, however, treatment was associated with an 81% lower hazard of diabetes diagnosis compared with no implantation. The same study also found a 51% lower risk of high blood pressure in the HGNS group after that same two-year mark.
That delayed effect matters. The researchers believe the body needs time to recover from chronic oxygen deprivation before the metabolic benefits become measurable. Restoring proper breathing doesn’t flip a switch; it gradually reduces the physiological stress that drives insulin resistance and high blood pressure in the first place.
The study’s follow-up timeframe was too short to definitively observe a change in long-term cardiovascular outcomes like arrhythmias, coronary artery disease, or heart failure, though the data does indicate the risks of these diseases are decreasing. The authors describe it as the first study to rigorously demonstrate that HGNS is associated with the prevention of hypertension and diabetes.
Why Sleep Apnea and Diabetes Are So Closely Linked
The connection between OSA and metabolic disease isn’t new, but it keeps getting sharper with each large study. The airway blockage that OSA causes lowers oxygen levels during sleep, decreasing sleep quality and raising the risk of diabetes and cardiovascular disease. HGNS has now been associated with potential reductions in the incidence of both diabetes and hypertension, suggesting possible longer-term cardiovascular benefits.
The mechanism runs through insulin resistance. When oxygen levels fall repeatedly through the night, the body’s stress response activates, releasing cortisol and adrenaline. Over time, this chronic activation interferes with how cells respond to insulin – the hormone that regulates blood sugar. The JAMA Otolaryngology study specifically examined whether HGNS is associated with a lower incidence of cardiovascular disease in patients with OSA, but the diabetes finding may be the most clinically immediate.
The relationship between type 2 diabetes and OSA runs in both directions – each condition makes the other worse. OSA drives insulin resistance; poor blood sugar control, in turn, worsens airway muscle function. Breaking that cycle appears to require treating the sleep disorder first.
Research published in a 2024 study in the New England Journal of Medicine found that OSA was associated with substantially elevated cardiovascular risk, and that consistent treatment reduced that elevated risk meaningfully. Earlier University of Chicago Medicine research found that CPAP in patients with prediabetes can lower their risk of progressing to full diabetes when used for eight hours nightly.
Sleep Apnea Treatment for Diabetes: Expanding the Options
Sleep apnea is the most common sleep-related breathing disorder, characterized by repetitive pauses in breathing, periods of shallow breathing, or collapse of the upper airway during sleep, resulting in poor ventilation and sleep disruption. The standard treatment for decades has been CPAP therapy, which delivers continuous pressurized air through a mask to hold the airway open. It works – but only if people actually use it, and a substantial portion don’t.
HGNS fills a gap for patients who genuinely cannot tolerate CPAP. The STAR trial (Stimulation Therapy for Apnea Reduction), which supported the original FDA approval, found that Inspire therapy reduced apnea events by 68% in patients with moderate-to-severe OSA who couldn’t use CPAP. The 2026 JAMA Otolaryngology data now adds a crucial dimension: the benefits extend well beyond the airway itself into long-term metabolic health.
There’s also growing interest in weight-loss medications as a secondary pathway. A 2024 phase 3 trial published in the New England Journal of Medicine found that tirzepatide – the active ingredient in Mounjaro, a type 2 diabetes medication – reduced the severity of sleep apnea by nearly two-thirds in adults with both OSA and obesity. That finding positions GLP-1 medications as a potential complement to device-based treatment, particularly for patients whose OSA is driven largely by excess weight.
Dr. Neil Kondamuri, an otolaryngology resident at University of Chicago Medicine and lead researcher on the JAMA Otolaryngology study, described obstructive sleep apnea as a “silent danger we don’t talk about enough.” His team also acknowledged that the current study’s time frame was too short to definitively link HGNS to long-term outcomes like lower risk of dangerous heart rhythm disorders, heart attack, or heart failure. Larger, longer studies are needed before those connections can be confirmed.
Read More: Sleep Apnea Sufferers Might Be Able to Say Goodbye to CPAP Machines for Good
What to Do Now
Sleep apnea affects roughly 1 in 10 people globally, and up to 80% of U.S. adults with OSA remain undiagnosed. The most common reason: the symptoms – loud snoring, daytime fatigue, waking with headaches – get dismissed as normal tiredness rather than flagged as a medical condition. If you share a bed with someone who gasps, snores heavily, or seems to stop breathing at night, that warrants a conversation with a doctor. A sleep study can confirm the diagnosis, often done at home with a portable monitor.
If you’ve already been diagnosed with OSA and find CPAP therapy unworkable – whether because of claustrophobia, pressure discomfort, or simply poor sleep quality with the mask on – HGNS is worth asking about. A sleep-trained otolaryngologist (an ear, nose, and throat specialist with sleep medicine expertise) can evaluate whether your airway anatomy and apnea pattern make you a good candidate.
The 81% reduction in diabetes risk reported in the JAMA Otolaryngology data is a retrospective finding – meaning it observed outcomes in people who had already received the implant, rather than randomly assigning people to treatment in a controlled trial. That limits how firmly causation can be claimed. But the direction of the evidence, across multiple treatment types and multiple studies, keeps pointing the same way: treating sleep apnea consistently and effectively reduces the downstream risk of some of the most serious chronic diseases in adults. The mechanism matters less than the result, and the result is becoming harder to ignore.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.